ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学会発表・講演等
  2. 口頭発表

Molecular imaging of cancer hypoxia and its application for internal radiotherapy targeting hypoxic microenvironment

https://repo.qst.go.jp/records/65669
https://repo.qst.go.jp/records/65669
7dfd2e3f-8c37-4a6b-b9ac-20d127048272
Item type 会議発表用資料 / Presentation(1)
公開日 2015-06-03
タイトル
タイトル Molecular imaging of cancer hypoxia and its application for internal radiotherapy targeting hypoxic microenvironment
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_c94f
資源タイプ conference object
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 佐賀, 恒夫

× 佐賀, 恒夫

WEKO 646860

佐賀, 恒夫

Search repository
佐賀 恒夫

× 佐賀 恒夫

WEKO 646861

en 佐賀 恒夫

Search repository
抄録
内容記述タイプ Abstract
内容記述 Molecular imaging of cancer hypoxia and its application for internal radiotherapy targeting hypoxic microenvironment
\nTsuneo Saga, MD, PhD
Molecular Imaging Center, National Institute of Radiological Sciences (Japan)
\nThe presence of hypoxia in cancers is known to increase not only their refractoriness to treatment, but also their malignant potential. The information of cancer hypoxia, therefore, is important for the management of cancer patients such as prediction of treatment response and the selection of appropriate treatment strategy. At present, two kinds of PET probes, nitroimidazole derivatives such as 18F-FMISO and 60, 62, 64Cu-ATSM, are applied for clinical evaluation of cancer hypoxia, and their usefulness in predicting treatment response and the potential applicability for radiation treatment planning has been reported. We have conducted clinical studies using 18F-FAZA, 2nd generation nitroimidazole probe, for lung cancer and head and neck cancer patients receiving chemoradiotherapy, and evaluated the relationship of 18F-FAZA uptake and treatment response and survival of the patients. Clinical studies using 62Cu-ATSM, which accumulates in hypoxic tissue by different mechanism from that of nitroimidazoles, is also ongoing in several institutions in Japan, showing promising results.
Our basic studies have shown that the intratumoral area showing high Cu-ATSM uptake constructs cancer stem cell-rich region. We, then, evaluated the potential of Cu-ATSM labeled with 64Cu, which emits -rays and Auger electrons in addition to positrons, as an internal radiotherapy (IRT) probe targeting hypoxic microenvironment. Experimental IRT study in mouse model has shown that the administration of high dose of 64Cu-ATSM showed significant therapeutic effect and reduced the number of cancer stem cells. For the safe clinical application, high physiological uptake of 64Cu-ATSM in the liver should be reduced, and we developed a method to reduce high physiological uptake in the liver.
In this symposium, I would like to briefly summarize clinical results of hypoxia PET and also our preclinical evaluations aiming for the development of IRT targeting hypoxic microenvironment.
会議概要(会議名, 開催地, 会期, 主催者等)
内容記述タイプ Other
内容記述 15th International Congress of Radiation Research(ICRR2015)
発表年月日
日付 2015-05-26
日付タイプ Issued
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 20:57:34.641692
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3